US5851526A
(en)
*
|
1985-04-19 |
1998-12-22 |
Ludwig Institute For Cancer Research |
Methods of treating colon cancer utilizing tumor-specific antibodies
|
US6020145A
(en)
*
|
1989-06-30 |
2000-02-01 |
Bristol-Myers Squibb Company |
Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
|
SE470273B
(sv)
*
|
1990-09-24 |
1993-12-20 |
Idl Immunodeveloplab Ab |
Cytokeratinfragment, deras framställning och användning, framställning av monoklonala antikroppar och testkit för epitelialcancer
|
US6749853B1
(en)
|
1992-03-05 |
2004-06-15 |
Board Of Regents, The University Of Texas System |
Combined methods and compositions for coagulation and tumor treatment
|
US5965132A
(en)
*
|
1992-03-05 |
1999-10-12 |
Board Of Regents, The University Of Texas System |
Methods and compositions for targeting the vasculature of solid tumors
|
US5877289A
(en)
*
|
1992-03-05 |
1999-03-02 |
The Scripps Research Institute |
Tissue factor compositions and ligands for the specific coagulation of vasculature
|
US6036955A
(en)
*
|
1992-03-05 |
2000-03-14 |
The Scripps Research Institute |
Kits and methods for the specific coagulation of vasculature
|
WO1993017715A1
(en)
*
|
1992-03-05 |
1993-09-16 |
Board Of Regents, The University Of Texas System |
Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
|
US6004555A
(en)
*
|
1992-03-05 |
1999-12-21 |
Board Of Regents, The University Of Texas System |
Methods for the specific coagulation of vasculature
|
US5660827A
(en)
*
|
1992-03-05 |
1997-08-26 |
Board Of Regents, The University Of Texas System |
Antibodies that bind to endoglin
|
US6093399A
(en)
*
|
1992-03-05 |
2000-07-25 |
Board Of Regents, The University Of Texas System |
Methods and compositions for the specific coagulation of vasculature
|
AU4953693A
(en)
*
|
1992-08-25 |
1994-03-15 |
Medac Gesellschaft Fur Klinische Spezialpraparate Mbh |
Antibody/radioisotope conjugate for tumor diagnosis and/or therapy
|
US7105159B1
(en)
*
|
1992-11-05 |
2006-09-12 |
Sloan-Kettering Institute For Cancer Research |
Antibodies to prostate-specific membrane antigen
|
US7070782B1
(en)
*
|
1992-11-05 |
2006-07-04 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen
|
GB9300686D0
(en)
*
|
1993-01-15 |
1993-03-03 |
Imp Cancer Res Tech |
Compounds for targeting
|
DK85193D0
(da)
*
|
1993-07-16 |
1993-07-16 |
Cancerforskningsfondet Af 1989 |
Suppression of inhibitors
|
JPH09500650A
(ja)
*
|
1993-07-26 |
1997-01-21 |
ケイ.オー.テクノロジー インコーポレイテッド |
ガン治療薬の主薬としての遺伝子の異なる対立遺伝子の阻害剤
|
US6569432B1
(en)
*
|
1995-02-24 |
2003-05-27 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen and uses thereof
|
US20030108545A1
(en)
*
|
1994-02-10 |
2003-06-12 |
Patricia Rockwell |
Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
|
US6448077B1
(en)
*
|
1994-02-10 |
2002-09-10 |
Imclone Systems, Inc. |
Chimeric and humanized monoclonal antibodies specific to VEGF receptors
|
US5830448A
(en)
*
|
1994-06-16 |
1998-11-03 |
Genentech, Inc. |
Compositions and methods for the treatment of tumors
|
DE69519929T2
(de)
*
|
1994-07-11 |
2001-05-23 |
Univ Texas |
Verfahren und zusammensetzungen für die spezifische koagulation von tumorgefässen
|
GB9415492D0
(en)
*
|
1994-08-01 |
1994-09-21 |
Celltech Ltd |
Biological products
|
US5792456A
(en)
*
|
1994-08-04 |
1998-08-11 |
Bristol-Myers Squibb Company |
Mutant BR96 antibodies reactive with human carcinomas
|
US6086875A
(en)
*
|
1995-01-17 |
2000-07-11 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
US6030613A
(en)
*
|
1995-01-17 |
2000-02-29 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
US6485726B1
(en)
|
1995-01-17 |
2002-11-26 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
US7429646B1
(en)
|
1995-06-05 |
2008-09-30 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor-like 2
|
US7166295B1
(en)
*
|
1995-05-26 |
2007-01-23 |
Meir Strahilevitz |
Methods of treatment and diagnostic visualization, particularly in cancer
|
US6521211B1
(en)
*
|
1995-06-07 |
2003-02-18 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Methods of imaging and treatment with targeted compositions
|
US6379669B1
(en)
*
|
1995-08-04 |
2002-04-30 |
Akhouri A. Sinha |
Targeting of organs by immunoconjugates
|
CA2229741C
(en)
|
1995-08-18 |
2012-05-08 |
The Government Of The United States Of America |
Functional role of adrenomedullin (am) and the gene-related product (pamp) in human pathology and physiology
|
US6497881B1
(en)
*
|
1995-11-30 |
2002-12-24 |
New York University |
High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US20040253246A1
(en)
*
|
1996-02-23 |
2004-12-16 |
Israeli Ron S. |
Prostate-specific membrane antigen and uses thereof
|
US20020098194A1
(en)
*
|
1996-03-21 |
2002-07-25 |
Paul V. Lehmann |
Methods for inducing immunity
|
US7964190B2
(en)
|
1996-03-22 |
2011-06-21 |
Human Genome Sciences, Inc. |
Methods and compositions for decreasing T-cell activity
|
US6635743B1
(en)
|
1996-03-22 |
2003-10-21 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule II and methods of use
|
US7381407B1
(en)
|
1996-03-25 |
2008-06-03 |
Medarex, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
US6962981B1
(en)
*
|
1996-03-25 |
2005-11-08 |
Medarex, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
US6107090A
(en)
*
|
1996-05-06 |
2000-08-22 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
EP0832653A1
(de)
*
|
1996-09-20 |
1998-04-01 |
Max-Delbrück-Centrum Für Molekulare Medizin |
Verwenddung von Cytokinen und cytotoxischen Substanzen in einem neuen Verfahren zur Tumorbehandlung
|
GB9708265D0
(en)
|
1997-04-24 |
1997-06-18 |
Nycomed Imaging As |
Contrast agents
|
US6132730A
(en)
*
|
1997-01-22 |
2000-10-17 |
Board Of Regents, The University Of Texas System |
Combined tissue factor and factor VIIa methods and compositions for coagulation and tumor treatment
|
HUP0001261A3
(en)
*
|
1997-04-30 |
2001-11-28 |
Univ Washington Seattle |
Method of imaging cell death in vivo
|
AU2469299A
(en)
*
|
1998-01-23 |
1999-08-09 |
Cornell Research Foundation Inc. |
Purified populations of stem cells
|
AU757554B2
(en)
*
|
1998-02-11 |
2003-02-27 |
Bracco International B.V. |
Angiogenesis targeting molecules
|
WO1999040912A1
(en)
*
|
1998-02-11 |
1999-08-19 |
The Brigham And Women's Hospital, Inc. |
Method of stimulating apoptosis using trichothecene mycotoxins
|
DE69943022D1
(de)
|
1998-03-19 |
2011-01-20 |
Human Genome Sciences Rockville |
Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
|
US6524553B2
(en)
*
|
1998-03-31 |
2003-02-25 |
Bristol-Myers Squibb Pharma Company |
Quinolone vitronectin receptor antagonist pharmaceuticals
|
US6548663B1
(en)
|
1998-03-31 |
2003-04-15 |
Bristol-Myers Squibb Pharma Company |
Benzodiazepine vitronectin receptor antagonist pharmaceuticals
|
ATE295369T1
(de)
|
1998-03-31 |
2005-05-15 |
Bristol Myers Squibb Pharma Co |
Pharmazeutika zur bildgebung der angiogenischen krankheiten
|
US6537520B1
(en)
|
1998-03-31 |
2003-03-25 |
Bristol-Myers Squibb Pharma Company |
Pharmaceuticals for the imaging of angiogenic disorders
|
US6852318B1
(en)
*
|
1998-05-08 |
2005-02-08 |
The Regents Of The University Of California |
Methods for detecting and inhibiting angiogenesis
|
ES2347027T3
(es)
|
1998-05-22 |
2010-10-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Moleculas bifuncionales y terapias basadas en las mismas.
|
JP5064608B2
(ja)
*
|
1998-05-26 |
2012-10-31 |
スローン−ケッタリング インスティトゥート フォー カンサー リサーチ |
アルファ粒子放出構成物およびその使用方法
|
US6962702B2
(en)
|
1998-06-22 |
2005-11-08 |
Immunomedics Inc. |
Production and use of novel peptide-based agents for use with bi-specific antibodies
|
WO2000002584A2
(en)
|
1998-07-13 |
2000-01-20 |
Board Of Regents, The University Of Texas System |
Cancer treatment methods using antibodies to aminophospholipids
|
US6406693B1
(en)
|
1998-07-13 |
2002-06-18 |
Board Of Regents, The University Of Texas System |
Cancer treatment methods using antibodies to aminophospholipids
|
US6818213B1
(en)
|
1998-07-13 |
2004-11-16 |
Board Of Regents, The University Of Texas System |
Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
|
BR9912053A
(pt)
*
|
1998-07-13 |
2001-04-03 |
Univ Texas |
Processos de tratamento de câncer utilizando conjugados terapêuticos que se ligam a aminofosfolipìdios
|
EP1520588B1
(en)
|
1998-07-13 |
2014-12-24 |
Board Of Regents, The University Of Texas System |
Uses of antibodies to aminophospholipids for cancer treatment
|
NZ511677A
(en)
|
1998-12-18 |
2003-10-31 |
Du Pont Pharm Co |
Vitronectin receptor antagonist pharmaceuticals
|
TR200101757T2
(tr)
|
1998-12-18 |
2001-12-21 |
Dupont Pharmaceuticais Company |
Vitronektin reseptör antagonisti farmasötikler
|
US6569402B1
(en)
|
1998-12-18 |
2003-05-27 |
Bristol-Myers Squibb Pharma Company |
Vitronectin receptor antagonist pharmaceuticals
|
US6511649B1
(en)
|
1998-12-18 |
2003-01-28 |
Thomas D. Harris |
Vitronectin receptor antagonist pharmaceuticals
|
US6794518B1
(en)
|
1998-12-18 |
2004-09-21 |
Bristol-Myers Squibb Pharma Company |
Vitronectin receptor antagonist pharmaceuticals
|
EP1131099A2
(en)
*
|
1999-01-15 |
2001-09-12 |
Light Sciences Corporation |
Noninvasive vascular therapy
|
US6602274B1
(en)
*
|
1999-01-15 |
2003-08-05 |
Light Sciences Corporation |
Targeted transcutaneous cancer therapy
|
US6454789B1
(en)
|
1999-01-15 |
2002-09-24 |
Light Science Corporation |
Patient portable device for photodynamic therapy
|
EP2357192A1
(en)
|
1999-02-26 |
2011-08-17 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
US6703020B1
(en)
*
|
1999-04-28 |
2004-03-09 |
Board Of Regents, The University Of Texas System |
Antibody conjugate methods for selectively inhibiting VEGF
|
ES2223705T3
(es)
|
1999-04-28 |
2005-03-01 |
Board Of Regents, The University Of Texas System |
Composiciones y metodos para el tratamiento de cancer mediante inhibi cion selectiva del vegf.
|
US7049140B1
(en)
*
|
1999-04-29 |
2006-05-23 |
Vanderbilt University |
X-ray guided drug delivery
|
US6903196B1
(en)
|
1999-06-17 |
2005-06-07 |
Utah Ventures Ii, L.P. |
Methods for identifying and isolating tissue-specific lumen-exposed molecules
|
US20040001826A1
(en)
|
1999-06-30 |
2004-01-01 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
US7291714B1
(en)
|
1999-06-30 |
2007-11-06 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
US6924359B1
(en)
|
1999-07-01 |
2005-08-02 |
Yale University |
Neovascular-targeted immunoconjugates
|
DE60039240D1
(de)
*
|
1999-07-01 |
2008-07-31 |
Univ Yale |
Neovaskulär gerichtete immunkonjugate
|
AU6208100A
(en)
*
|
1999-07-12 |
2001-01-30 |
Board Of Regents, The University Of Texas System |
Cancer treatment using angiopoietins targeted to aminophospholipids
|
AU7067200A
(en)
*
|
1999-08-23 |
2001-03-19 |
Organogenesis Inc. |
Skin care compositions and treatments
|
US20040214783A1
(en)
|
2002-05-08 |
2004-10-28 |
Terman David S. |
Compositions and methods for treatment of neoplastic disease
|
US20030232056A1
(en)
|
1999-09-10 |
2003-12-18 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
EP1229934B1
(en)
|
1999-10-01 |
2014-03-05 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
US7361338B2
(en)
*
|
1999-10-05 |
2008-04-22 |
Agensys, Inc. |
Methods to inhibit growth of prostate cancer cells
|
US6790631B1
(en)
|
1999-10-05 |
2004-09-14 |
Agensys, Inc. |
G protein-coupled receptor up-regulated in prostate cancer and uses thereof
|
EP1231944A2
(en)
*
|
1999-11-15 |
2002-08-21 |
University Of Southern California |
Targeted delivery of therapeutic and diagnostic moieties
|
EP1267935A2
(en)
|
2000-01-12 |
2003-01-02 |
Light Sciences Corporation |
Novel treatment for eye disease
|
AU2002219944B2
(en)
|
2000-11-28 |
2008-02-21 |
Medimmune, Llc |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
US7740841B1
(en)
*
|
2000-01-28 |
2010-06-22 |
Sunnybrook Health Science Center |
Therapeutic method for reducing angiogenesis
|
EP1257289A1
(en)
*
|
2000-02-08 |
2002-11-20 |
The Penn State Research Foundation |
Immunotherapy using interleukin 13 receptor subunit alpha 2
|
PT1257297E
(pt)
|
2000-02-24 |
2006-12-29 |
Philogen Spa |
Composições e método para tratamento da angiogénese em lesões patológicas
|
EP1263776A2
(en)
*
|
2000-03-16 |
2002-12-11 |
University Of Pittsburgh |
Peptides targeting specifically tumor-derived endothelial cells
|
PT1268799E
(pt)
*
|
2000-03-31 |
2009-05-11 |
Imclone Llc |
Anticorpos antagonistas de ve-caderina sem efeitos adversos sobre a permeabilidade vascular
|
JP2003530839A
(ja)
|
2000-04-12 |
2003-10-21 |
プリンシピア ファーマスーティカル コーポレイション |
アルブミン融合タンパク質
|
US6471968B1
(en)
|
2000-05-12 |
2002-10-29 |
Regents Of The University Of Michigan |
Multifunctional nanodevice platform
|
US20030195707A1
(en)
*
|
2000-05-25 |
2003-10-16 |
Schork Nicholas J |
Methods of dna marker-based genetic analysis using estimated haplotype frequencies and uses thereof
|
US20020077775A1
(en)
*
|
2000-05-25 |
2002-06-20 |
Schork Nicholas J. |
Methods of DNA marker-based genetic analysis using estimated haplotype frequencies and uses thereof
|
US8263739B2
(en)
*
|
2000-06-02 |
2012-09-11 |
Bracco Suisse Sa |
Compounds for targeting endothelial cells, compositions containing the same and methods for their use
|
US7700359B2
(en)
|
2000-06-02 |
2010-04-20 |
Novartis Vaccines And Diagnostics, Inc. |
Gene products differentially expressed in cancerous cells
|
EP2279757A3
(en)
|
2000-06-02 |
2011-08-03 |
Bracco Suisse SA |
Compounds for targeting endothelial cells
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
EP2431054A3
(en)
|
2000-06-15 |
2013-03-06 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
ATE494304T1
(de)
|
2000-06-16 |
2011-01-15 |
Human Genome Sciences Inc |
Immunspezifisch bindende antikörper gegen blys
|
JP2004509072A
(ja)
*
|
2000-06-28 |
2004-03-25 |
ブリストル−マイヤーズ スクイブ カンパニー |
選択的アンドロゲン受容体モジュレーター並びにその同定、設計及び使用方法
|
ATE448226T1
(de)
|
2000-09-01 |
2009-11-15 |
Novartis Vaccines & Diagnostic |
Aza heterocyclische derivate und ihre therapeutische verwendung
|
US20030028018A1
(en)
*
|
2000-09-11 |
2003-02-06 |
Chiron Coporation |
Quinolinone derivatives
|
DE60132937T2
(de)
*
|
2000-09-11 |
2009-02-12 |
Novartis Vaccines and Diagnostics, Inc., Emeryville |
Verfahren zur Herstellung von Benzimidazol-2-yl -Chinolinonderivaten
|
US20030082103A1
(en)
*
|
2000-10-11 |
2003-05-01 |
Targesome, Inc. |
Targeted therapeutic lipid constructs having cell surface targets
|
US20030129223A1
(en)
*
|
2000-10-11 |
2003-07-10 |
Targesome, Inc. |
Targeted multivalent macromolecules
|
US20030133972A1
(en)
*
|
2000-10-11 |
2003-07-17 |
Targesome, Inc. |
Targeted multivalent macromolecules
|
CZ20031262A3
(en)
*
|
2000-10-16 |
2004-03-17 |
Neopharm, Inc. |
Liposomal formulation of mitoxantrone
|
WO2002036073A2
(en)
*
|
2000-11-02 |
2002-05-10 |
Smithkline Beecham Corporation |
Receptor antagonist-lipid conjugates and delivery vehicles containing same
|
DE10060729A1
(de)
*
|
2000-12-07 |
2002-06-20 |
Messer Griesheim Gmbh |
Schmelzofen
|
US7083784B2
(en)
|
2000-12-12 |
2006-08-01 |
Medimmune, Inc. |
Molecules with extended half-lives, compositions and uses thereof
|
US6979556B2
(en)
|
2000-12-14 |
2005-12-27 |
Genentech, Inc. |
Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
|
EP1683865A3
(en)
|
2001-02-02 |
2006-10-25 |
Eli Lilly & Company |
Mammalian proteins and in particular CD200
|
EP1366058B1
(en)
|
2001-02-09 |
2011-01-26 |
Human Genome Sciences, Inc. |
Human g-protein chemokine receptor (ccr5) hdgnr10
|
US20020197210A1
(en)
*
|
2001-03-08 |
2002-12-26 |
Bednarski Mark David |
Stabilized therapeutic and imaging agents
|
US20030118585A1
(en)
*
|
2001-10-17 |
2003-06-26 |
Agy Therapeutics |
Use of protein biomolecular targets in the treatment and visualization of brain tumors
|
US20040198960A1
(en)
*
|
2001-03-29 |
2004-10-07 |
Janoff Edward N |
Human monoclonal antibodies against capsular polysaccharides of streptococcus pneumoniae
|
WO2002082044A2
(en)
*
|
2001-04-03 |
2002-10-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Method of imaging cell death in vivo
|
US20050013778A1
(en)
*
|
2001-04-03 |
2005-01-20 |
Theseus Imaging Corporation |
Methods and compositions for predicting the response to a therapeutic regimen in a subject having a disease associated with cell death
|
US6843980B2
(en)
*
|
2001-04-03 |
2005-01-18 |
Theseus Imaging, Corp. |
Methods for using annexin for detecting cell death in vivo and treating associated conditions
|
CA2444632A1
(en)
|
2001-04-13 |
2002-10-24 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
WO2002096460A1
(en)
*
|
2001-05-30 |
2002-12-05 |
Cornell Research Foundation, Inc. |
Endopeptidase/anti-psma antibody fusion proteins for treatment of cancer
|
AU2002318169B2
(en)
*
|
2001-06-01 |
2007-10-18 |
Cornell Research Foundation, Inc. |
Modified antibodies to prostate-specific membrane antigen and uses thereof
|
US7514078B2
(en)
*
|
2001-06-01 |
2009-04-07 |
Cornell Research Foundation, Inc. |
Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
|
US7666414B2
(en)
*
|
2001-06-01 |
2010-02-23 |
Cornell Research Foundation, Inc. |
Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
|
US20020193569A1
(en)
*
|
2001-06-04 |
2002-12-19 |
Idec Pharmaceuticals Corporation |
Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
|
EP1515707A4
(en)
*
|
2001-06-20 |
2005-10-19 |
Imclone Systems Inc |
METHOD FOR THE TREATMENT OF ATHEROSCLEROSIS AND OTHER INFLAMMATORY DISEASES
|
EP1416960A4
(en)
*
|
2001-07-13 |
2006-02-22 |
Imclone Systems Inc |
VEGFR-1 ANTIBODY FOR THE TREATMENT OF BREAST CANCER
|
CA2450073C
(en)
|
2001-07-25 |
2017-08-29 |
Biomarin Pharmaceutical Inc. |
Compositions and methods for modulating blood-brain barrier transport
|
CA2454251A1
(en)
*
|
2001-08-10 |
2003-02-20 |
Imclone Systems Incorporated |
Isolation and mobilization of stem cells expressing vegfr-1
|
IL160229A0
(en)
*
|
2001-08-10 |
2004-07-25 |
Genset Sa |
Polynucleotides, polypeptides encoded thereby and their use
|
CN100513414C
(zh)
|
2001-08-27 |
2009-07-15 |
杰南技术公司 |
进行抗体表达和装配的系统
|
JP2005527474A
(ja)
|
2001-09-20 |
2005-09-15 |
コーネル リサーチ ファンデーション インコーポレーテッド |
前立腺特異的膜抗原に特異的な結合剤を用いて、皮膚障害を治療するかまたは防止するための方法および組成物
|
US20030129193A1
(en)
*
|
2001-09-27 |
2003-07-10 |
Board Of Regents, The University Of Texas System And Peregrine Pharmaceuticals, Inc. |
Combined methods for tumor vasculature coaguligand treatment
|
US7906102B2
(en)
|
2001-10-03 |
2011-03-15 |
Vanderbilt University |
Ligands to radiation-induced molecules
|
US7306925B2
(en)
|
2001-11-09 |
2007-12-11 |
Vanderbilt University |
Phage antibodies to radiation-inducible neoantigens
|
CA2463672A1
(en)
*
|
2001-10-15 |
2003-04-24 |
Immunomedics, Inc. |
Direct targeting binding proteins
|
US20050215472A1
(en)
|
2001-10-23 |
2005-09-29 |
Psma Development Company, Llc |
PSMA formulations and uses thereof
|
CA2464239C
(en)
|
2001-10-23 |
2016-07-12 |
Psma Development Company, L.L.C. |
Psma antibodies and protein multimers
|
ATE489103T1
(de)
|
2001-10-26 |
2010-12-15 |
Scripps Research Inst |
Gezielte thrombose durch gewebefaktor polypeptiden
|
EP2277910A1
(en)
|
2001-12-21 |
2011-01-26 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
JP4376629B2
(ja)
|
2002-01-08 |
2009-12-02 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
癌性胸部細胞において差次的に発現された遺伝子産物およびその使用方法
|
US20030167033A1
(en)
*
|
2002-01-23 |
2003-09-04 |
James Chen |
Systems and methods for photodynamic therapy
|
WO2003068054A2
(en)
*
|
2002-02-13 |
2003-08-21 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health Services |
Identification of ovarian cancer tumor markers and therapeutic targets
|
US7261876B2
(en)
|
2002-03-01 |
2007-08-28 |
Bracco International Bv |
Multivalent constructs for therapeutic and diagnostic applications
|
US20050250700A1
(en)
*
|
2002-03-01 |
2005-11-10 |
Sato Aaron K |
KDR and VEGF/KDR binding peptides
|
US7211240B2
(en)
|
2002-03-01 |
2007-05-01 |
Bracco International B.V. |
Multivalent constructs for therapeutic and diagnostic applications
|
US7794693B2
(en)
|
2002-03-01 |
2010-09-14 |
Bracco International B.V. |
Targeting vector-phospholipid conjugates
|
US8623822B2
(en)
|
2002-03-01 |
2014-01-07 |
Bracco Suisse Sa |
KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
|
US20050100963A1
(en)
*
|
2002-03-01 |
2005-05-12 |
Dyax Corporation |
KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
|
US7985402B2
(en)
|
2002-03-01 |
2011-07-26 |
Bracco Suisse Sa |
Targeting vector-phospholipid conjugates
|
US7666979B2
(en)
|
2002-03-01 |
2010-02-23 |
Bracco International B.V. |
Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
|
ES2362931T3
(es)
*
|
2002-03-04 |
2011-07-15 |
Imclone Llc |
Anticuerpos humanos específicos contra kdr y usos de los mismos.
|
CA2481747A1
(en)
|
2002-04-12 |
2003-10-23 |
Medimmune, Inc. |
Recombinant anti-interleukin-9 antibodies
|
MY138268A
(en)
*
|
2002-05-15 |
2009-05-29 |
Janssen Pharmaceutica Nv |
N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders
|
ATE461713T1
(de)
*
|
2002-05-29 |
2010-04-15 |
Immunomedics Inc |
Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren
|
US20040022726A1
(en)
*
|
2002-06-03 |
2004-02-05 |
Goldenberg David M. |
Methods and compositions for intravesical therapy of bladder cancer
|
AU2003274463B2
(en)
|
2002-06-10 |
2009-10-29 |
University Of Rochester |
Gene differentially expressed in breast and bladder cancer and encoded polypeptides
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US7585501B2
(en)
|
2002-06-14 |
2009-09-08 |
Stowers Institute For Medical Research |
Compositions and methods for treating kidney disease
|
KR101143035B1
(ko)
|
2002-06-14 |
2012-05-08 |
이뮤노메딕스, 인코오포레이티드 |
단클론 항체 hPAM4
|
NZ596825A
(en)
|
2002-07-15 |
2013-06-28 |
Univ Texas |
Duramycin peptides and their use in imaging
|
ES2575522T3
(es)
|
2002-07-18 |
2016-06-29 |
Janssen Pharmaceutica Nv |
Inhibidores de quinasas con triazina sustituida
|
AU2003262650B2
(en)
|
2002-08-14 |
2009-10-29 |
Macrogenics, Inc. |
FcgammaRIIB-specific antibodies and methods of use thereof
|
US20040224986A1
(en)
|
2002-08-16 |
2004-11-11 |
Bart De Corte |
Piperidinyl targeting compounds that selectively bind integrins
|
AR041010A1
(es)
*
|
2002-08-16 |
2005-04-27 |
Janssen Pharmaceutica Nv |
Compuestos de acido piperidinoil carboxilico utiles como antagonistas selectivos del receptor de integrina
|
US20050256157A1
(en)
*
|
2002-08-23 |
2005-11-17 |
Chiron Corporation |
Combination therapy with CHK1 inhibitors
|
JP4613130B2
(ja)
*
|
2002-08-23 |
2011-01-12 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
ベンゾイミダゾールキノリノンおよびそれらの使用
|
US7825132B2
(en)
*
|
2002-08-23 |
2010-11-02 |
Novartis Vaccines And Diagnostics, Inc. |
Inhibition of FGFR3 and treatment of multiple myeloma
|
LT2891666T
(lt)
|
2002-10-16 |
2017-10-10 |
Purdue Pharma L.P. |
Antikūnai, kurie prisiriša su ląstelėmis susijusį ca 125/o722p ir jų naudojimo būdas
|
US20040136998A1
(en)
*
|
2002-10-30 |
2004-07-15 |
Bander Neil H. |
Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen
|
WO2004044161A2
(en)
*
|
2002-11-06 |
2004-05-27 |
Fraunhofer Usa |
Expression of foreign sequences in plants using trans-activation system
|
US7491509B2
(en)
|
2003-02-03 |
2009-02-17 |
Fraunhofer Usa, Inc. |
System for expression of genes in plants
|
US7683238B2
(en)
*
|
2002-11-12 |
2010-03-23 |
iBio, Inc. and Fraunhofer USA, Inc. |
Production of pharmaceutically active proteins in sprouted seedlings
|
US7692063B2
(en)
*
|
2002-11-12 |
2010-04-06 |
Ibio, Inc. |
Production of foreign nucleic acids and polypeptides in sprout systems
|
US7838527B2
(en)
*
|
2002-11-13 |
2010-11-23 |
Novartis Vaccines And Diagnostics, Inc. |
Methods of treating cancer and related methods
|
EP1581103A4
(en)
*
|
2002-12-12 |
2007-01-31 |
Manoa Medical Inc |
PERKUTANE REMOVAL OF A KEEPER NODE USING CONTRAST IMAGE IDENTIFICATION
|
AU2004204494B2
(en)
|
2003-01-09 |
2011-09-29 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
DE60323677D1
(de)
*
|
2003-01-10 |
2008-10-30 |
Millennium Pharm Inc |
Verfahren zur bestimmung des wiederauftretens von prostata krebs
|
AU2004205684A1
(en)
|
2003-01-23 |
2004-08-05 |
Genentech, Inc. |
Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
|
ATE472338T1
(de)
|
2003-02-20 |
2010-07-15 |
Seattle Genetics Inc |
Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs
|
DE10311248A1
(de)
*
|
2003-03-14 |
2004-09-30 |
Müller-Hermelink, Hans Konrad, Prof. Dr. |
Humaner monoklonaler Antikörper
|
WO2008109433A2
(en)
|
2007-03-02 |
2008-09-12 |
The Cleveland Clinic Foundation |
Anti-angiogenic peptides
|
EP1613273B1
(en)
|
2003-04-11 |
2012-06-13 |
MedImmune, LLC |
Recombinant il-9 antibodies and uses thereof
|
EP1664322B1
(en)
|
2003-05-22 |
2013-07-10 |
Fraunhofer USA, Inc. |
Recombinant carrier molecule for expression, delivery and purification of target polypeptides
|
DE602004015454D1
(de)
|
2003-06-25 |
2008-09-11 |
Peregrine Pharmaceuticals Inc |
Verfahren und vorrichtung zur kontinuierlichen radioaktiven markierung von proteinen im grossen massstab
|
WO2005000086A2
(en)
*
|
2003-06-30 |
2005-01-06 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
FRAGMENTS OF NKp44 AND NKp46 FOR TARGETING VIRAL-INFECTED AND TUMOR CELLS
|
WO2005086612A2
(en)
*
|
2003-07-29 |
2005-09-22 |
Immunomedics, Inc. |
Fluorinated carbohydrate conjugates
|
AU2004263538B2
(en)
*
|
2003-08-08 |
2009-09-17 |
Immunomedics, Inc. |
Bispecific antibodies for inducing apoptosis of tumor and diseased cells
|
ATE422880T1
(de)
|
2003-08-26 |
2009-03-15 |
Smithkline Beecham Corp |
Heterofunktionelle copolymere von glycerol und polyethylenglykol, ihre konjugate und zusammensetzungen
|
WO2005074417A2
(en)
*
|
2003-09-03 |
2005-08-18 |
Salk Institute For Biological Studies |
Multiple antigen detection assays and reagents
|
CA2543820C
(en)
*
|
2003-11-07 |
2012-07-10 |
Chiron Corporation |
Methods for synthesizing quinolinone compounds
|
EP1682516A2
(en)
*
|
2003-11-13 |
2006-07-26 |
Janssen Pharmaceutica N.V. |
Immobilized n-substituted tricyclic 3-aminopyrazoles for the identification of biomolecular targets
|
US7371381B2
(en)
|
2003-12-12 |
2008-05-13 |
Amgen Inc. |
Anti-galanin antibodies and uses thereof
|
KR101627588B1
(ko)
|
2003-12-23 |
2016-06-07 |
제넨테크, 인크. |
신규 항-il13 항체 및 그 용도
|
WO2005070456A2
(en)
*
|
2004-01-09 |
2005-08-04 |
Millennium Pharmaceuticals, Inc. |
Diagnosing and treating female reproductive tract or chilhood cancer with pmsa antibodies
|
US20090155266A1
(en)
*
|
2004-01-16 |
2009-06-18 |
Yale University |
Methods and Compositions Relating to Vascular Endothelial Growth Factor and TH2 Mediated Inflammatory Diseases
|
CN102816241B
(zh)
|
2004-02-09 |
2015-07-22 |
人类基因科学公司 |
清蛋白融合蛋白
|
CN1922306B
(zh)
*
|
2004-02-20 |
2010-10-06 |
美国弗劳恩霍夫股份有限公司 |
用于植物中克隆表达的系统和方法
|
US7875624B2
(en)
*
|
2004-02-20 |
2011-01-25 |
Novartis Vaccines And Diagnostics, Inc. |
Modulating and measuring cellular adhesion
|
WO2005094882A1
(en)
*
|
2004-03-03 |
2005-10-13 |
Millennium Pharmaceuticals, Inc. |
Modified antibodies to prostate-specific membrane antigen and uses thereof
|
JP2008505853A
(ja)
|
2004-04-13 |
2008-02-28 |
クインテセンス バイオサイエンシーズ インコーポレーティッド |
細胞傷害性薬剤としての非天然のリボヌクレアーゼ複合体
|
PT1745078E
(pt)
|
2004-04-23 |
2009-09-17 |
Conjuchem Biotechnologies Inc |
Método para a purificação de conjugados de albumina
|
EP1756165A2
(en)
*
|
2004-06-02 |
2007-02-28 |
Sidney Kimmel Cancer Center |
Tissue-specific imaging and therapeutical agents targeting proteins expressed on lung endothelial cell surface
|
WO2005117848A2
(en)
*
|
2004-06-02 |
2005-12-15 |
Sidney Kimmel Cancer Center |
Vascular targets for detecting, imaging and treating neoplasia or neovasculature
|
TW200600784A
(en)
*
|
2004-06-02 |
2006-01-01 |
Sidney Kimmel Cancer Ct |
Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface
|
US7846438B2
(en)
|
2004-08-03 |
2010-12-07 |
Biogen Idec Ma Inc. |
Methods of promoting neurite outgrowth with soluble TAJ polypeptides
|
US20090104119A1
(en)
*
|
2004-08-25 |
2009-04-23 |
Majoros Istvan J |
Dendrimer Based Compositions And Methods Of Using The Same
|
EP3073267A1
(en)
|
2004-09-21 |
2016-09-28 |
Medimmune, Inc. |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
EP1809326A4
(en)
|
2004-10-27 |
2009-11-04 |
Medimmune Inc |
MODULATION OF ANTIBODY SPECIFICITY BY MEASURING ADAPTATION OF ITS AFFINITY TO AN APPARENT ANTIGEN
|
CA2590671A1
(en)
*
|
2004-11-18 |
2006-05-26 |
Imclone Systems Incorporated |
Antibodies against vascular endothelial growth factor receptor-1
|
KR101281501B1
(ko)
*
|
2004-12-09 |
2013-07-15 |
얀센 바이오테크 인코포레이티드 |
항인테그린 면역 컨쥬게이트, 방법 및 용도
|
US20060183750A1
(en)
*
|
2005-01-27 |
2006-08-17 |
Chiron Corporation |
Treatment of metastasized tumors
|
EP2548575A1
(en)
|
2005-02-15 |
2013-01-23 |
Duke University |
Anti-CD19 antibodies that mediate ADCC for use in treating autoimmune diseases
|
AU2006214032B2
(en)
*
|
2005-02-18 |
2012-03-08 |
E. R. Squibb & Sons, L.L.C. |
Monoclonal antibodies against prostate specific membrane antigen (PSMA) lacking in fucosyl residues
|
CN101124249B
(zh)
*
|
2005-02-18 |
2011-06-29 |
米德列斯公司 |
抗前列腺特异性膜抗原(psma)的人单克隆抗体
|
EP2511299A1
(en)
|
2005-04-19 |
2012-10-17 |
Seattle Genetics, Inc. |
Humanized anti-CD70 binding agents and uses thereof
|
EP3827747A1
(en)
|
2005-04-28 |
2021-06-02 |
Otsuka Pharmaceutical Co., Ltd. |
Pharma-informatics system
|
CA2607281C
(en)
|
2005-05-05 |
2023-10-03 |
Duke University |
Anti-cd19 antibody therapy for autoimmune disease
|
BRPI0611069A2
(pt)
|
2005-05-06 |
2010-11-09 |
Zymogenetics Inc |
anticorpo monoclonal, anticorpo humanizado, fragmento de anticorpo, uso de um antagonista, e, hibridoma
|
KR101319122B1
(ko)
|
2005-05-13 |
2013-10-23 |
노파르티스 아게 |
약물 저항성 암을 치료하는 방법
|
EP1885393A4
(en)
|
2005-05-18 |
2011-03-02 |
Childrens Hosp & Res Ct Oak |
METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST CHLAMYDIA INFECTIONS
|
CN101218228A
(zh)
*
|
2005-05-23 |
2008-07-09 |
诺瓦提斯公司 |
4-氨基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮乳酸盐的结晶和其它形式
|
US7541367B2
(en)
*
|
2005-05-31 |
2009-06-02 |
Janssen Pharmaceutica, N.V. |
3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
|
US20060281768A1
(en)
*
|
2005-06-10 |
2006-12-14 |
Gaul Michael D |
Thienopyrimidine and thienopyridine kinase modulators
|
US20060281788A1
(en)
*
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
|
US8071768B2
(en)
*
|
2005-06-10 |
2011-12-06 |
Janssen Pharmaceutica, N.V. |
Alkylquinoline and alkylquinazoline kinase modulators
|
US7825244B2
(en)
*
|
2005-06-10 |
2010-11-02 |
Janssen Pharmaceutica Nv |
Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
|
WO2007002543A2
(en)
|
2005-06-23 |
2007-01-04 |
Medimmune, Inc. |
Antibody formulations having optimized aggregation and fragmentation profiles
|
KR101245462B1
(ko)
|
2005-07-08 |
2013-03-20 |
바이오겐 아이덱 엠에이 인코포레이티드 |
Sp35 항체 및 그의 용도
|
AU2006341615A1
(en)
*
|
2005-08-03 |
2007-10-18 |
Fraunhofer Usa, Inc. |
Compositions and methods for production of immunoglobulins
|
JP2009502180A
(ja)
|
2005-08-03 |
2009-01-29 |
アデレイド リサーチ アンド イノベーション ピーティーワイ リミテッド |
多糖シンターゼ
|
PT1919503E
(pt)
|
2005-08-10 |
2015-01-05 |
Macrogenics Inc |
Identificação e manipulação de anticorpos com a regiões de fc variantes e métodos de utilização dos mesmos
|
US20070041934A1
(en)
*
|
2005-08-12 |
2007-02-22 |
Regents Of The University Of Michigan |
Dendrimer based compositions and methods of using the same
|
EP1945240B1
(en)
|
2005-09-16 |
2016-12-28 |
Raptor Pharmaceutical Inc |
Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
|
US7422899B2
(en)
|
2005-10-05 |
2008-09-09 |
Biogen Idec Ma Inc. |
Antibodies to the human prolactin receptor
|
US20070086979A1
(en)
|
2005-10-13 |
2007-04-19 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive disease
|
JP2009511628A
(ja)
|
2005-10-18 |
2009-03-19 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
Flt3キナーゼの阻害方法
|
KR20150055628A
(ko)
|
2005-11-04 |
2015-05-21 |
제넨테크, 인크. |
안질환 치료를 위한 보체 경로 억제제의 용도
|
CN101500592A
(zh)
|
2005-11-07 |
2009-08-05 |
斯克利普斯研究院 |
控制组织因子信号转导特异性的组合物和方法
|
US8039432B2
(en)
*
|
2005-11-09 |
2011-10-18 |
Conjuchem, Llc |
Method of treatment of diabetes and/or obesity with reduced nausea side effect
|
DOP2006000277A
(es)
|
2005-12-12 |
2007-08-31 |
Bayer Pharmaceuticals Corp |
Anticuerpos anti mn y métodos para su utilización
|
DK1966214T3
(en)
*
|
2005-12-21 |
2017-02-13 |
Janssen Pharmaceutica Nv |
TRIAZOLPYRIDAZINES AS TYROSINKINASA MODULATORS
|
CN101384623B
(zh)
*
|
2005-12-22 |
2013-07-24 |
常山凯捷健生物药物研发(河北)有限公司 |
白蛋白与治疗剂的预成型偶联物的制备方法
|
CA2642054C
(en)
*
|
2006-02-13 |
2017-11-21 |
Fraunhofer Usa, Inc. |
Influenza antigens, vaccine compositions, and related methods
|
WO2008048344A2
(en)
*
|
2006-02-13 |
2008-04-24 |
Fraunhofer Usa, Inc. |
Bacillus anthracis antigens, vaccine compositions, and related methods
|
BRPI0707779B8
(pt)
*
|
2006-02-13 |
2021-05-25 |
Fraunhofer Usa Inc |
antígeno isolado, composição de vacina e método para produção de uma proteína antígeno
|
EP1999148B8
(en)
|
2006-03-06 |
2014-03-05 |
Medlmmune, LLC |
Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
US7504106B2
(en)
|
2006-03-14 |
2009-03-17 |
Boris Skurkovich |
Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
|
EP1996716B1
(en)
|
2006-03-20 |
2011-05-11 |
The Regents of the University of California |
Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
|
CA2649739C
(en)
|
2006-04-20 |
2015-09-01 |
Janssen Pharmaceutica N.V. |
Inhibitors of c-fms kinase
|
CA2649755C
(en)
|
2006-04-20 |
2014-12-02 |
Janssen Pharmaceutica N.V. |
Method of inhibiting c-kit kinase
|
US7414050B2
(en)
|
2006-04-20 |
2008-08-19 |
Janssen Pharmaceutica, N.V. |
Inhibitors of c-fms kinase
|
US8697716B2
(en)
*
|
2006-04-20 |
2014-04-15 |
Janssen Pharmaceutica Nv |
Method of inhibiting C-KIT kinase
|
BRPI0713426A2
(pt)
|
2006-06-14 |
2012-10-09 |
Macrogenics Inc |
métodos de tratar, diminuir a progressão, ou melhorar um ou mais sintomas de um distúrbio, e de prevenir ou retardar o inìcio de um distúrbio
|
US8840882B2
(en)
*
|
2006-06-23 |
2014-09-23 |
Quintessence Biosciences, Inc. |
Modified ribonucleases
|
LT2029173T
(lt)
|
2006-06-26 |
2016-11-10 |
Macrogenics, Inc. |
Fc riib specifiniai antikūnai ir jų panaudojimo būdai
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
US8298801B2
(en)
*
|
2006-07-17 |
2012-10-30 |
Quintessence Biosciences, Inc. |
Methods and compositions for the treatment of cancer
|
KR101501660B1
(ko)
|
2006-09-01 |
2015-03-11 |
지모제넥틱스, 인코포레이티드 |
Il―31 단클론 항체의 가변 영역 서열 및 사용 방법
|
WO2008030735A2
(en)
|
2006-09-06 |
2008-03-13 |
Janssen Pharmaceutical N.V. |
Biomarkers for assessing response to c-met treatment
|
CA2665826A1
(en)
|
2006-10-16 |
2008-04-24 |
Medimmune, Llc |
Molecules with reduced half-lives, compositions and uses thereof
|
CA2667621A1
(en)
*
|
2006-10-27 |
2008-11-06 |
Trustees Of Boston University |
Targeted split biomolecular conjugates for the treatment of diseases, malignancies and disorders, and methods of their production
|
WO2008070593A2
(en)
|
2006-12-01 |
2008-06-12 |
Seattle Genetics, Inc. |
Variant target binding agents and uses thereof
|
KR20150004933A
(ko)
|
2006-12-18 |
2015-01-13 |
제넨테크, 인크. |
항-notch3 길항제 항체 및 notch3-관련 질환의 예방 및 치료에 있어서 그의 용도
|
NZ577976A
(en)
|
2007-01-09 |
2011-12-22 |
Biogen Idec Inc |
Sp35 antibodies and uses thereof
|
WO2008094896A1
(en)
*
|
2007-01-31 |
2008-08-07 |
Janssen Pharmaceutica, N.V. |
N-substituted tricyclic 3-aminopyrazoles as anti-mitotic tubulin polymerization inhibitors
|
EP2069404B1
(en)
|
2007-02-14 |
2011-01-05 |
Vaccinex, Inc. |
Humanized anti-cd100 antibodies
|
WO2008118324A2
(en)
|
2007-03-26 |
2008-10-02 |
Macrogenics, Inc. |
Composition and method of treating cancer with an anti-uroplakin ib antibody
|
US20090088376A1
(en)
*
|
2007-04-19 |
2009-04-02 |
The Regents Of The University Of Michigan |
Dendrimer based compositions and methods of using the same
|
EA009327B1
(ru)
*
|
2007-04-27 |
2007-12-28 |
Петр Генриевич ЛОХОВ |
Способ получения противоопухолевой вакцины на основе поверхностных антигенов эндотелиальных клеток
|
WO2008134643A2
(en)
*
|
2007-04-28 |
2008-11-06 |
Fraunhofer Usa, Inc. |
Trypanosoma antigens, vaccine compositions, and related methods
|
KR20100017514A
(ko)
|
2007-05-07 |
2010-02-16 |
메디뮨 엘엘씨 |
항 icos 항체, 및 종양, 이식 및 자가면역성 질환 치료에서의 이의 용도
|
MX2020011303A
(es)
|
2007-05-14 |
2021-12-17 |
Astrazeneca Ab |
Metodos para reducir niveles de eosinofilos.
|
JP5548123B2
(ja)
*
|
2007-06-21 |
2014-07-16 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
6−{ジフルオロ[6−(1−メチル−1H−ピラゾル−4−イル)[1,2,4]トリアゾロ[4,3−b]ピリダジン−3−イル]メチル}キノリンの多形および水和物の形態、塩、ならびに製造方法
|
CA2692933C
(en)
|
2007-07-11 |
2016-10-18 |
Fraunhofer Usa, Inc. |
Yersinia pestis antigens, vaccine compositions, and related methods
|
WO2009014708A2
(en)
|
2007-07-23 |
2009-01-29 |
Cell Genesys, Inc. |
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
|
EP3492488A1
(en)
|
2007-08-22 |
2019-06-05 |
The Regents of The University of California |
Activatable binding polypeptides and methods of identification and use thereof
|
US8916135B2
(en)
*
|
2007-08-22 |
2014-12-23 |
Colorado School Of Mines |
Lanthanide nanoparticle conjugates and uses thereof
|
EP2197491A4
(en)
|
2007-09-04 |
2011-01-12 |
Univ California |
HIGHAFFINE ANTI-PROSTATE STEM CELL ANTIGEN (PSCA) ANTIBODIES TO CANCER AND TO THE DETECTION OF CANCER
|
EP2197911A2
(en)
|
2007-09-14 |
2010-06-23 |
Amgen Inc. |
Homogeneous antibody populations
|
US8697062B2
(en)
*
|
2007-10-08 |
2014-04-15 |
Quintessence Biosciences, Inc. |
Compositions and methods for ribonuclease-based therapeutics
|
JO3240B1
(ar)
*
|
2007-10-17 |
2018-03-08 |
Janssen Pharmaceutica Nv |
c-fms مثبطات كيناز
|
EP2219672B1
(en)
|
2007-11-09 |
2016-02-17 |
Peregrine Pharmaceuticals, Inc. |
Anti-vegf antibody compositions and methods
|
WO2009070642A1
(en)
|
2007-11-28 |
2009-06-04 |
Medimmune, Llc |
Protein formulation
|
EP2229583B1
(en)
|
2007-12-06 |
2019-04-10 |
Genalyte Inc. |
Label-free nucleic acid synthesis monitoring system and method
|
AU2008341050B2
(en)
|
2007-12-26 |
2013-10-24 |
Vaccinex, Inc. |
Anti-C35 antibody combination therapies and methods
|
US8252834B2
(en)
|
2008-03-12 |
2012-08-28 |
The Regents Of The University Of Michigan |
Dendrimer conjugates
|
WO2009118300A1
(en)
|
2008-03-25 |
2009-10-01 |
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by down-regulating frizzled-4 and/or frizzled-1
|
CA2723197C
(en)
|
2008-05-02 |
2017-09-19 |
Seattle Genetics, Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
WO2009148896A2
(en)
|
2008-05-29 |
2009-12-10 |
Nuclea Biotechnologies, LLC |
Anti-phospho-akt antibodies
|
US8058406B2
(en)
|
2008-07-09 |
2011-11-15 |
Biogen Idec Ma Inc. |
Composition comprising antibodies to LINGO or fragments thereof
|
US20100069616A1
(en)
*
|
2008-08-06 |
2010-03-18 |
The Regents Of The University Of California |
Engineered antibody-nanoparticle conjugates
|
US8968705B2
(en)
|
2008-08-22 |
2015-03-03 |
Colorado School Of Mines |
Gold/lanthanide nanoparticle conjugates and uses thereof
|
EP2328928A2
(en)
|
2008-08-25 |
2011-06-08 |
Dana-Farber Cancer Institute, Inc. |
Conserved influenza hemagglutinin epitope and antibodies thereto
|
WO2010027501A2
(en)
|
2008-09-05 |
2010-03-11 |
Duke University |
Anti-lipid antibodies
|
JP5778577B2
(ja)
|
2008-09-19 |
2015-09-16 |
メディミューン,エルエルシー |
Dll4に対する抗体およびその使用
|
WO2010037046A1
(en)
|
2008-09-28 |
2010-04-01 |
Fraunhofer Usa, Inc. |
Humanized neuraminidase antibody and methods of use thereof
|
US8889635B2
(en)
|
2008-09-30 |
2014-11-18 |
The Regents Of The University Of Michigan |
Dendrimer conjugates
|
BRPI0920743A2
(pt)
|
2008-10-01 |
2016-09-20 |
Quintessence Biosciences Inc |
ribonucleases terapeuticas
|
JP2012505243A
(ja)
|
2008-10-09 |
2012-03-01 |
ノースイースタン・ユニバーシティ |
多機能の自己集合性高分子ナノシステム
|
EP3572796B8
(en)
|
2008-10-27 |
2023-01-18 |
Genalyte, Inc. |
Biosensors based on optical probing and sensing
|
US9393304B2
(en)
|
2008-10-29 |
2016-07-19 |
Ablynx N.V. |
Formulations of single domain antigen binding molecules
|
CN102272154A
(zh)
|
2008-10-29 |
2011-12-07 |
惠氏有限责任公司 |
单域抗原结合性分子的纯化方法
|
WO2010051502A2
(en)
*
|
2008-10-31 |
2010-05-06 |
Biogen Idec Ma Inc. |
Light targeting molecules and uses thereof
|
US8642280B2
(en)
|
2008-11-07 |
2014-02-04 |
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Teneurin and cancer
|
US9017644B2
(en)
|
2008-11-07 |
2015-04-28 |
The Regents Of The University Of Michigan |
Methods of treating autoimmune disorders and/or inflammatory disorders
|
EP2358392B1
(en)
|
2008-11-12 |
2019-01-09 |
MedImmune, LLC |
Antibody formulation
|
CA2748158A1
(en)
|
2008-12-23 |
2010-07-01 |
Astrazeneca Ab |
Targeted binding agents directed to .alpha.5.beta.1 and uses thereof
|
WO2010078526A1
(en)
|
2008-12-31 |
2010-07-08 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
AU2010203353B2
(en)
|
2009-01-12 |
2016-06-16 |
Cytomx Therapeutics, Inc |
Modified antibody compositions, methods of making and using thereof
|
US8852608B2
(en)
|
2009-02-02 |
2014-10-07 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
EP2396035A4
(en)
|
2009-02-12 |
2012-09-12 |
Human Genome Sciences Inc |
USE OF ANTAGONISTS OF PROTEIN STIMULATING LYMPHOCYTES B TO PROMOTE GRAFT TOLERANCE
|
HUE059078T2
(hu)
|
2009-02-20 |
2022-10-28 |
Enhanx Biopharm Inc |
Glutation-alapú hatóanyagszállító rendszer
|
US20110311521A1
(en)
|
2009-03-06 |
2011-12-22 |
Pico Caroni |
Novel therapy for anxiety
|
EP2241323A1
(en)
|
2009-04-14 |
2010-10-20 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tenascin-W and brain cancers
|
AR076284A1
(es)
|
2009-04-29 |
2011-06-01 |
Bayer Schering Pharma Ag |
Inmunoconjugados de antimesotelina y usos de los mismos
|
IL295075A
(en)
|
2009-05-06 |
2022-09-01 |
Laboratory Skin Care Inc |
Preparations for administration through the skin that include complexes of an active substance with calcium phosphate and methods of using them
|
CA2760890C
(en)
|
2009-05-08 |
2019-08-20 |
Vaccinex, Inc. |
Anti-cd100 antibodies and methods for using the same
|
GB0909904D0
(en)
|
2009-06-09 |
2009-07-22 |
Affitech As |
Product
|
GB0909906D0
(en)
|
2009-06-09 |
2009-07-22 |
Affitech As |
Antibodies
|
JP2012532846A
(ja)
|
2009-07-09 |
2012-12-20 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
インビボ腫瘍脈管構造画像処理
|
WO2011020079A1
(en)
|
2009-08-13 |
2011-02-17 |
Calmune Corporation |
Antibodies against human respiratory syncytial virus (rsv) and methods of use
|
EP2292266A1
(en)
|
2009-08-27 |
2011-03-09 |
Novartis Forschungsstiftung, Zweigniederlassung |
Treating cancer by modulating copine III
|
WO2011036118A1
(en)
|
2009-09-22 |
2011-03-31 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mex-3
|
EP2483307A1
(en)
|
2009-09-29 |
2012-08-08 |
Fraunhofer USA, Inc. |
Influenza hemagglutinin antibodies, compositions, and related methods
|
US9005926B2
(en)
|
2009-10-02 |
2015-04-14 |
Biogen Idec Ma Inc. |
Methods of preventing and removing trisulfide bonds
|
RU2583298C2
(ru)
|
2009-10-07 |
2016-05-10 |
Макродженикс, Инк. |
ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc-УЧАСТОК, КОТОРЫЕ ДЕМОНСТРИРУЮТ ПОВЫШЕННУЮ ЭФФЕКТОРНУЮ ФУНКЦИЮ БЛАГОДАРЯ ИЗМЕНЕНИЯМ СТЕПЕНИ ФУКОЗИЛИРОВАНИЯ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
US8945508B2
(en)
|
2009-10-13 |
2015-02-03 |
The Regents Of The University Of Michigan |
Dendrimer compositions and methods of synthesis
|
WO2011045352A2
(en)
|
2009-10-15 |
2011-04-21 |
Novartis Forschungsstiftung |
Spleen tyrosine kinase and brain cancers
|
WO2011059586A2
(en)
|
2009-10-30 |
2011-05-19 |
The Regents Of The University Of Michigan |
Multifunctional small molecules
|
US20120213801A1
(en)
|
2009-10-30 |
2012-08-23 |
Ekaterina Gresko |
Phosphorylated Twist1 and cancer
|
PL2504364T3
(pl)
|
2009-11-24 |
2017-12-29 |
Medimmune Limited |
Ukierunkowane środki wiążące przeciwko B7-H1
|
US20110201076A1
(en)
|
2010-01-22 |
2011-08-18 |
Colorado School Of Mines |
Harvesting micro algae
|
TW201129384A
(en)
|
2010-02-10 |
2011-09-01 |
Immunogen Inc |
CD20 antibodies and uses thereof
|
GB201002238D0
(en)
|
2010-02-10 |
2010-03-31 |
Affitech As |
Antibodies
|
NZ724971A
(en)
|
2010-02-24 |
2019-06-28 |
Immunogen Inc |
Folate receptor 1 antibodies and immunoconjugates and uses thereof
|
WO2011107586A1
(en)
|
2010-03-05 |
2011-09-09 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, |
Smoc1, tenascin-c and brain cancers
|
WO2011131611A1
(en)
|
2010-04-19 |
2011-10-27 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Modulating xrn1
|
WO2011154485A1
(en)
|
2010-06-10 |
2011-12-15 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mammalian sterile 20-like kinase 3
|
BR112012031638B1
(pt)
|
2010-07-09 |
2021-01-12 |
Janssen Vaccines & Prevention B.V. |
anticorpo anti-rsv ou fragmento de ligação de antígeno do mesmo, anticorpo multivalente, composição farmacêutica, uso de anticorpo ou fragmento de ligação de antígeno, método de detectar infecção por rsv, e, ácido nucleico isolado
|
US20120100166A1
(en)
|
2010-07-15 |
2012-04-26 |
Zyngenia, Inc. |
Ang-2 Binding Complexes and Uses Thereof
|
AU2011277983C1
(en)
|
2010-07-16 |
2016-09-29 |
Ablynx Nv |
Modified single domain antigen binding molecules and uses thereof
|
BR112013005145B1
(pt)
|
2010-09-02 |
2022-02-15 |
Vaccinex, Inc |
Anticorpo isolado ou seu fragmento de ligação ao antígeno que se liga especificamente ao cxcl13, composição e uso de uma composição
|
EP2614080A1
(en)
|
2010-09-10 |
2013-07-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Phosphorylated twist1 and metastasis
|
CN106563128B
(zh)
|
2010-10-22 |
2020-05-22 |
西雅图遗传学公司 |
以奥里斯他汀为主的抗体药物结合物和结合mTOR的抑制剂在制备治疗癌症药物中的用途
|
EP2632434A1
(en)
|
2010-10-26 |
2013-09-04 |
AC Immune S.A. |
Liposome-based construct comprising a peptide modified through hydrophobic moieties
|
KR20140075639A
(ko)
|
2010-10-27 |
2014-06-19 |
더 리서치 파운데이션 포 더 스테이트 유니버시티 오브 뉴욕 |
암 치료법을 위한 e-카드헤린의 가용성 세포외 도메인의 표적화 조성물 및 관련 방법
|
RU2604490C2
(ru)
|
2010-11-05 |
2016-12-10 |
Займворкс Инк. |
ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ
|
WO2012061778A2
(en)
|
2010-11-05 |
2012-05-10 |
Genalyte, Inc. |
Optical analyte detection systems and methods of use
|
WO2012065937A1
(en)
|
2010-11-15 |
2012-05-24 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Anti-fungal agents
|
GB201020738D0
(en)
|
2010-12-07 |
2011-01-19 |
Affitech Res As |
Antibodies
|
JP6130350B2
(ja)
|
2011-03-30 |
2017-05-17 |
アブリンクス エン.ヴェー. |
TNFαに対する単一ドメイン抗体で免疫障害を処置する方法
|
EP3318273B1
(en)
|
2011-04-01 |
2019-08-21 |
ImmunoGen, Inc. |
Methods for increasing efficacy of folr1 cancer therapy
|
WO2012143495A2
(de)
|
2011-04-21 |
2012-10-26 |
Bayer Intellectual Property Gmbh |
Neue binder-wirkstoff konjugate (adcs) und ihre verwendung
|
US9562252B2
(en)
|
2011-05-13 |
2017-02-07 |
Biogen Ma Inc. |
Methods of preventing and removing trisulfide bonds
|
AU2012258637B2
(en)
|
2011-05-24 |
2017-07-20 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
EP2717911A1
(en)
|
2011-06-06 |
2014-04-16 |
Novartis Forschungsstiftung, Zweigniederlassung |
Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
|
WO2012170740A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
WO2012170742A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Treatment and prevention of cancer with hmgb1 antagonists
|
WO2013019730A1
(en)
|
2011-07-29 |
2013-02-07 |
The Washington University |
Antibodies to tip-1 and grp78
|
WO2013043864A1
(en)
*
|
2011-09-23 |
2013-03-28 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods related to endothelial targeting
|
US10598653B2
(en)
|
2011-11-01 |
2020-03-24 |
Bionomics Inc. |
Methods of blocking cancer stem cell growth
|
CA2853951A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Antibodies and methods of treating cancer
|
AU2012332593B2
(en)
|
2011-11-01 |
2016-11-17 |
Bionomics, Inc. |
Anti-GPR49 antibodies
|
WO2013067057A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
KR102052774B1
(ko)
|
2011-11-04 |
2019-12-04 |
자임워크스 인코포레이티드 |
Fc 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계
|
US20140314787A1
(en)
|
2011-11-08 |
2014-10-23 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute |
Treatment for neurodegenerative diseases
|
EP2776838A1
(en)
|
2011-11-08 |
2014-09-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Early diagnostic of neurodegenerative diseases
|
WO2013085550A2
(en)
|
2011-12-05 |
2013-06-13 |
Duke University |
V1v2 immunogens
|
US9402911B2
(en)
|
2011-12-08 |
2016-08-02 |
The Regents Of The University Of Michigan |
Multifunctional small molecules
|
CA2859255A1
(en)
|
2011-12-14 |
2013-06-20 |
Seattle Genetics, Inc. |
New antibody drug conjugates (adcs) and the use thereof
|
WO2013102825A1
(en)
|
2012-01-02 |
2013-07-11 |
Novartis Ag |
Cdcp1 and breast cancer
|
ES2725569T3
(es)
|
2012-02-10 |
2019-09-24 |
Seattle Genetics Inc |
Diagnóstico y tratamiento de cánceres que expresan CD30
|
JP6193275B2
(ja)
|
2012-03-02 |
2017-09-06 |
ヴァクシネックス, インコーポレイテッド |
B細胞媒介炎症性疾患を治療するための方法
|
US20130261010A1
(en)
|
2012-03-12 |
2013-10-03 |
The Board Of Trustees Of The University Of Illinois |
Optical analyte detection systems with magnetic enhancement and methods of use
|
EP2831112A1
(en)
|
2012-03-29 |
2015-02-04 |
Friedrich Miescher Institute for Biomedical Research |
Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
|
WO2013151649A1
(en)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Glycan-interacting compounds
|
WO2013169693A1
(en)
|
2012-05-09 |
2013-11-14 |
Bristol-Myers Squibb Company |
Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
|
WO2013166594A1
(en)
|
2012-05-10 |
2013-11-14 |
Zymeworks Inc. |
Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
|
MX362497B
(es)
|
2012-05-15 |
2019-01-21 |
Eisai Inc |
Un anticuerpo que se une específicamente al receptor alfa del folato y usos del mismo.
|
EP2855521A4
(en)
|
2012-05-24 |
2016-03-02 |
Mountgate Group Ltd |
COMPOSITIONS AND METHODS ASSOCIATED WITH THE PREVENTION AND TREATMENT OF RABIC INFECTION
|
US20150218238A1
(en)
|
2012-06-29 |
2015-08-06 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear |
Treating diseases by modulating a specific isoform of mkl1
|
EP2870242A1
(en)
|
2012-07-05 |
2015-05-13 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
New treatment for neurodegenerative diseases
|
WO2014006115A1
(en)
|
2012-07-06 |
2014-01-09 |
Novartis Ag |
Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
|
EP2882757B1
(en)
|
2012-08-07 |
2016-10-05 |
Janssen Pharmaceutica, N.V. |
Process for the preparation of heterocyclic ester derivatives
|
JOP20180012A1
(ar)
|
2012-08-07 |
2019-01-30 |
Janssen Pharmaceutica Nv |
عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
|
KR102134088B1
(ko)
|
2012-08-24 |
2020-07-14 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
|
RS60217B1
(sr)
|
2012-08-31 |
2020-06-30 |
Immunogen Inc |
Dijagnostički testovi i kompleti za detekciju folatnog receptora 1
|
WO2014122605A1
(en)
|
2013-02-08 |
2014-08-14 |
Friedrich Miescher Institute For Biomedical Research |
Novel methods for the targeted introduction of viruses into cells
|
AU2013205589A1
(en)
|
2013-03-08 |
2014-09-25 |
Vaccinex, Inc. |
Anti-CXCL13 antibodies and associated epitope sequences
|
WO2014143637A1
(en)
|
2013-03-15 |
2014-09-18 |
The Board Of Trustees Of The University Of Illinois |
Methods and compositions for enhancing immunoassays
|
CN105451767B
(zh)
|
2013-03-15 |
2019-10-18 |
泽恩格尼亚股份有限公司 |
多价和单价多特异性复合物及其用途
|
LT2981822T
(lt)
|
2013-05-06 |
2020-12-28 |
Scholar Rock, Inc. |
Kompozicijos ir būdai, skirti augimo faktoriaus moduliacijai
|
CA2953747A1
(en)
|
2013-06-28 |
2014-12-31 |
Auckland Uniservices Limited |
Amino acid and peptide conjugates and conjugation process
|
ES2761587T3
(es)
|
2013-08-07 |
2020-05-20 |
Friedrich Miescher Institute For Biomedical Res |
Nuevo método de cribado para el tratamiento de la ataxia de Friedreich
|
RU2725825C2
(ru)
|
2013-08-30 |
2020-07-06 |
Иммьюноджен Инк. |
Антитела и методы анализа для обнаружения рецептора фолиевой кислоты 1
|
EP3733868A3
(en)
|
2013-10-28 |
2021-01-13 |
DOTS Technology Corp. |
Allergen detection
|
WO2015085289A1
(en)
|
2013-12-06 |
2015-06-11 |
Millennium Pharmaceuticals, Inc. |
Combination of aurora kinase inhibitors and anti-cd30 antibodies
|
EP3086814B1
(de)
|
2013-12-23 |
2020-06-24 |
Bayer Pharma Aktiengesellschaft |
Binder-konjugate (adcs) mit ksp-inhibitoren
|
CA2944649C
(en)
|
2014-04-04 |
2022-06-21 |
Bionomics, Inc. |
Humanized antibodies that bind lgr5
|
EP3131584B1
(en)
|
2014-04-16 |
2022-01-12 |
Biocon Limited |
Stable protein formulations comprising a molar excess of sorbitol
|
EP3142700B1
(en)
|
2014-05-16 |
2021-03-03 |
Medimmune, LLC |
Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
|
US20170137824A1
(en)
|
2014-06-13 |
2017-05-18 |
Indranil BANERJEE |
New treatment against influenza virus
|
WO2015200073A1
(en)
|
2014-06-23 |
2015-12-30 |
Bionomics, Inc. |
Antibodies that bind lgr4
|
EP3157535A1
(en)
|
2014-06-23 |
2017-04-26 |
Friedrich Miescher Institute for Biomedical Research |
Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
|
EP3164129A1
(en)
|
2014-07-01 |
2017-05-10 |
Friedrich Miescher Institute for Biomedical Research |
Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
|
EP3172222A4
(en)
|
2014-07-24 |
2018-03-21 |
Washington University |
Compositions targeting radiation-induced molecules and methods of use thereof
|
EP3183002B1
(en)
|
2014-08-21 |
2021-03-03 |
Walter Reed Army Institute of Research |
Monoclonal antibodies for treatment of microbial infections
|
WO2016046768A1
(en)
|
2014-09-24 |
2016-03-31 |
Friedrich Miescher Institute For Biomedical Research |
Lats and breast cancer
|
PT3218005T
(pt)
|
2014-11-12 |
2023-04-11 |
Seagen Inc |
Compostos que interagem com glicano e métodos de uso
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
EP3220900B1
(en)
|
2014-11-21 |
2020-09-23 |
University of Maryland, Baltimore |
Targeted structure-specific particulate delivery systems
|
TWI695837B
(zh)
|
2014-12-04 |
2020-06-11 |
比利時商健生藥品公司 |
作為激酶調節劑之三唑並嗒
|
CA2970565A1
(en)
|
2014-12-15 |
2016-06-23 |
Bayer Pharma Aktiengesellschaft |
Antibody-drug conjugates (adcs) of ksp inhibitors with aglycosylated anti-tweakr antibodies
|
SG11201704962WA
(en)
|
2014-12-23 |
2017-07-28 |
Margaret Anne Brimble |
Amino acid and peptide conjugates and uses thereof
|
KR102261618B1
(ko)
|
2015-03-31 |
2021-06-04 |
메디뮨 리미티드 |
신규한 il33 형태, il33의 돌연변이된 형태, 항체, 검정 및 이의 이용 방법
|
AU2016282723B2
(en)
|
2015-06-22 |
2021-09-23 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates (ADCs) and antibody prodrug conjugates (APDCs) with enzymatically cleavable groups
|
CN107921145A
(zh)
|
2015-06-23 |
2018-04-17 |
拜耳医药股份有限公司 |
Ksp抑制剂与抗‑tweakr抗体的抗体药物缀合物(adc)
|
WO2016207104A1
(de)
|
2015-06-23 |
2016-12-29 |
Bayer Pharma Aktiengesellschaft |
Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-b7h3-antikörpern
|
CA2995838A1
(en)
|
2015-08-19 |
2017-02-23 |
Rutgers, The State University Of New Jersey |
Novel methods of generating antibodies
|
WO2017040324A1
(en)
|
2015-08-28 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for cells expressing a chimeric intracellular signaling molecule
|
WO2017040195A1
(en)
*
|
2015-08-28 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for cells expressing a chimeric intracellular signaling molecule
|
AU2016323153B2
(en)
|
2015-09-15 |
2021-04-22 |
Board Of Regents, The University Of Texas System |
T-cell receptor (TCR)-binding antibodies and uses thereof
|
EP3349796A4
(en)
|
2015-09-17 |
2019-05-29 |
ImmunoGen, Inc. |
THERAPEUTIC COMBINATIONS COMPRISING ANTI-FOLR1 IMMUNOCONJUGATES
|
WO2017060322A2
(en)
|
2015-10-10 |
2017-04-13 |
Bayer Pharma Aktiengesellschaft |
Ptefb-inhibitor-adc
|
US20180348224A1
(en)
|
2015-10-28 |
2018-12-06 |
Friedrich Miescher Institute For Biomedical Resear Ch |
Tenascin-w and biliary tract cancers
|
SG11201803213XA
(en)
|
2015-11-12 |
2018-05-30 |
Siamab Therapeutics Inc |
Glycan-interacting compounds and methods of use
|
BR112018017174A2
(pt)
|
2016-02-26 |
2019-01-02 |
Auckland Uniservices Ltd |
conjugados de aminoácido e peptídeo e processo de conjugação
|
WO2017161414A1
(en)
|
2016-03-22 |
2017-09-28 |
Bionomics Limited |
Administration of an anti-lgr5 monoclonal antibody
|
EP3432934B1
(de)
|
2016-03-24 |
2022-02-23 |
Bayer Pharma Aktiengesellschaft |
Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen
|
EP3919518A1
(en)
|
2016-06-15 |
2021-12-08 |
Bayer Pharma Aktiengesellschaft |
Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
|
JP7161266B2
(ja)
|
2016-08-05 |
2022-10-26 |
メディミューン,エルエルシー |
抗o2抗体およびその使用
|
AU2017326751A1
(en)
|
2016-09-16 |
2019-03-14 |
Bionomics Limited |
Antibody and checkpoint inhibitor combination therapy
|
EA201990895A1
(ru)
|
2016-10-19 |
2019-10-31 |
|
Антитела к о1 и варианты их применения
|
WO2018094143A1
(en)
|
2016-11-17 |
2018-05-24 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
BR112019011582A2
(pt)
|
2016-12-07 |
2019-10-22 |
Agenus Inc. |
anticorpos e métodos de utilização dos mesmos
|
CN110312533B
(zh)
|
2016-12-21 |
2023-11-03 |
拜耳公司 |
具有酶促可裂解的基团的细胞毒性活性剂的前药
|
IL310558A
(en)
|
2016-12-21 |
2024-03-01 |
Bayer Pharma AG |
Drug-antibody conjugates with enzymatically cleavable groups
|
CN110072556B
(zh)
|
2016-12-21 |
2023-05-02 |
拜耳制药股份公司 |
具有ksp抑制剂的特异性抗体药物缀合物(adc)
|
US20180230218A1
(en)
|
2017-01-04 |
2018-08-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
CA3221995A1
(en)
|
2017-02-08 |
2018-08-16 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
|
WO2018148595A1
(en)
|
2017-02-10 |
2018-08-16 |
Washington University |
Antibodies to tip1 and methods of use thereof
|
US11884732B2
(en)
|
2017-02-20 |
2024-01-30 |
Dragonfly Therapeutics, Inc. |
Proteins binding HER2, NKG2D and CD16
|
KR20240044544A
(ko)
|
2017-03-03 |
2024-04-04 |
씨젠 인크. |
글리칸-상호작용 화합물 및 사용 방법
|
EP3612556A1
(en)
|
2017-04-22 |
2020-02-26 |
Immunomic Therapeutics, Inc. |
Improved lamp constructs
|
US20200087365A1
(en)
|
2017-05-02 |
2020-03-19 |
Immunomic Therapeutics, Inc |
Improved lamp constructs comprising cancer antigens
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
CA3065328C
(en)
|
2017-06-21 |
2023-08-15 |
Gilead Sciences, Inc. |
Multispecific antibodies that target hiv gp120 and cd3
|
EP3668969A1
(en)
|
2017-08-18 |
2020-06-24 |
Friedrich Miescher Institute for Biomedical Research |
Novel methods for the targeted introduction of viruses into cells and tissues
|
KR20200066676A
(ko)
|
2017-10-11 |
2020-06-10 |
시애틀 지네틱스, 인크. |
항-cd30 항체 약물 콘주게이트 요법의 부작용을 감소시키는 방법
|
US11707522B2
(en)
|
2017-10-13 |
2023-07-25 |
Boehringer Ingelheim International Gmbh |
Human antibodies to Tn antigen
|
MX2020004563A
(es)
|
2017-11-01 |
2020-08-13 |
Seattle Genetics Inc |
Metodos de reduccion de efectos secundarios del tratamiento con conjugado anticuerpo anti-cd30-farmaco.
|
CN111587123A
(zh)
|
2017-11-09 |
2020-08-25 |
品通治疗有限公司 |
用于生成和使用人源化构象特异性磷酸化的τ抗体的方法和组合物
|
US20200360531A1
(en)
|
2018-01-31 |
2020-11-19 |
Bayer Aktiengesellschaft |
Antibody drug conjugates (adcs) with nampt inhibitors
|
JP2021512630A
(ja)
|
2018-02-08 |
2021-05-20 |
ドラゴンフライ セラピューティクス, インコーポレイテッド |
Nkg2d受容体を標的とする抗体可変ドメイン
|
KR20200135841A
(ko)
|
2018-03-23 |
2020-12-03 |
시애틀 지네틱스, 인크. |
고형 종양을 치료하기 위한 튜불린 교란제들을 포함하는 항체 약물 접합체들의 용도
|
US20210228729A1
(en)
|
2018-04-12 |
2021-07-29 |
Mediapharma S.R.L. |
Lgals3bp antibody-drug-conjugate and its use for the treatment of cancer
|
JP2021523158A
(ja)
|
2018-05-07 |
2021-09-02 |
ゲンマブ エー/エス |
抗pd−1抗体と抗組織因子抗体−薬物コンジュゲートとの組み合わせを用いるがんの治療方法
|
EP3814379A4
(en)
|
2018-05-07 |
2022-03-30 |
Genmab A/S |
METHOD OF TREATMENT OF CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE
|
US20210261647A1
(en)
|
2018-05-15 |
2021-08-26 |
Immunomic Therapeutics, Inc |
Lamp constructs comprising allergens
|
MX2020013832A
(es)
|
2018-06-18 |
2021-03-25 |
Bayer Ag |
Conjugados de ligante/agente activo dirigidos contra cxcr5 que tienen enlazadores escindibles enzimaticamente y un perfil de actividad mejorado.
|
CA3102859A1
(en)
|
2018-07-03 |
2020-01-09 |
Gilead Sciences, Inc. |
Antibodies that target hiv gp120 and methods of use
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
KR20210069679A
(ko)
|
2018-10-01 |
2021-06-11 |
씨젠 인크. |
항-cd30 항체 약물 컨쥬게이트 요법을 사용하여 말초 t 세포 림프종을 치료하는 방법
|
TW202034958A
(zh)
|
2018-10-30 |
2020-10-01 |
丹麥商珍美寶股份有限公司 |
使用抗血管內皮生長因子(vegf)抗體與抗組織因子(tf)抗體-藥物共軛體之組合以治療癌症之方法
|
EP3920968A1
(en)
|
2019-02-05 |
2021-12-15 |
Seagen Inc. |
Anti-cd228 antibodies and antibody-drug conjugates
|
JP2022524215A
(ja)
|
2019-03-28 |
2022-04-28 |
ダニスコ・ユーエス・インク |
改変抗体
|
WO2021013693A1
(en)
|
2019-07-23 |
2021-01-28 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates (adcs) with nampt inhibitors
|
US20220242962A1
(en)
|
2019-08-12 |
2022-08-04 |
Aptevo Research And Development Llc |
4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40
|
JP2022545732A
(ja)
*
|
2019-08-28 |
2022-10-28 |
バステラ カンパニー リミテッド |
エピジチオジオキソピペラジン誘導体又はその薬学的に許容される塩を含む、固形癌の予防又は治療用薬学的組成物
|
JP2022549495A
(ja)
|
2019-09-25 |
2022-11-25 |
シージェン インコーポレイテッド |
造血器がんの治療のための抗cd30 adc、抗pd-1、および化学療法剤の併用
|
BR112022005114A2
(pt)
|
2019-10-04 |
2022-06-21 |
Seagen Inc |
Anticorpo, composição farmacêutica, métodos para tratar câncer e para produzir um conjugado anticorpo-fármaco e um anticorpo, ácido nucleico, vetor, célula hospedeira, e, conjugado anticorpo-fármaco
|
US20240108703A1
(en)
|
2019-10-18 |
2024-04-04 |
Immunomic Therapeutics, Inc. |
Improved LAMP Constructs Comprising Cancer Antigens
|
AU2020379001A1
(en)
|
2019-11-04 |
2022-06-09 |
Paul RUBINSTEIN |
Anti-CD30 antibody-drug conjugates and their use for the treatment of HIV infection
|
TW202131954A
(zh)
|
2019-11-07 |
2021-09-01 |
丹麥商珍美寶股份有限公司 |
利用鉑類劑與抗組織因子抗體-藥物共軛體之組合來治療癌症之方法
|
US20230027495A1
(en)
|
2019-11-07 |
2023-01-26 |
Genmab A/S |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
|
TW202138388A
(zh)
|
2019-12-30 |
2021-10-16 |
美商西根公司 |
以非海藻糖苷化抗-cd70抗體治療癌症之方法
|
PE20221902A1
(es)
|
2020-01-24 |
2022-12-21 |
Pfizer |
Anticuerpos anti-e-selectina, composiciones y metodos de uso
|
KR20220146488A
(ko)
|
2020-01-31 |
2022-11-01 |
씨젠 인크. |
항-cd30 항체-약물 컨쥬게이트 및 비-호지킨 림프종의 치료를 위한 그의 용도
|
CN116390770A
(zh)
|
2020-05-13 |
2023-07-04 |
思进股份有限公司 |
使用抗cd30抗体-药物缀合物的组合治疗癌症的方法
|
EP4192871A1
(en)
|
2020-08-04 |
2023-06-14 |
Seagen Inc. |
Anti-cd228 antibodies and antibody-drug conjugates
|
CN116390750A
(zh)
|
2020-09-04 |
2023-07-04 |
罗格斯新泽西州立大学 |
SARS-CoV-2疫苗和抗体
|
EP4229081A1
(en)
|
2020-10-15 |
2023-08-23 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
IL302836A
(en)
|
2020-11-17 |
2023-07-01 |
Seagen Inc |
Methods for treating cancer with a combination of tocatinib and an anti-PD-1/anti-PD-L1 antibody
|
KR20230117379A
(ko)
|
2020-12-01 |
2023-08-08 |
압테보 리서치 앤드 디벨롭먼트 엘엘씨 |
이종이량체 psma 및 cd3-결합 이중특이적 항체
|
MX2023008261A
(es)
|
2021-01-13 |
2023-09-12 |
Memorial Sloan Kettering Cancer Center |
Conjugado de anticuerpo-derivado de pirrolobenzodiazepina.
|
KR20230146522A
(ko)
|
2021-01-13 |
2023-10-19 |
메모리얼 슬로안 케터링 캔서 센터 |
항-dll3 항체-약물 접합체
|
WO2022251446A1
(en)
|
2021-05-28 |
2022-12-01 |
Alexion Pharmaceuticals, Inc. |
Methods for detecting cm-tma biomarkers
|
CA3218481A1
(en)
|
2021-06-14 |
2022-12-22 |
argenx BV |
Anti-il-9 antibodies and methods of use thereof
|
AU2022304582A1
(en)
|
2021-06-29 |
2024-02-01 |
Seagen Inc. |
Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
|
IL309831A
(en)
|
2021-07-13 |
2024-02-01 |
BioNTech SE |
Multispecific binding agents against CD40 and CD137 in combined cancer therapy
|
IL311771A
(en)
|
2021-10-06 |
2024-05-01 |
BioNTech SE |
Multispecific binding agents against PD-L1 and CD137 in combination
|
CA3236735A1
(en)
|
2021-10-29 |
2023-05-04 |
Seagen Inc. |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate
|
WO2023083439A1
(en)
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Tlr7 agonist and combinations for cancer treatment
|
WO2023192436A1
(en)
|
2022-03-31 |
2023-10-05 |
Alexion Pharmaceuticals, Inc. |
Singleplex or multiplexed assay for complement markers in fresh biological samples
|
WO2023201201A1
(en)
|
2022-04-10 |
2023-10-19 |
Immunomic Therapeutics, Inc. |
Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof
|
WO2023213960A1
(en)
|
2022-05-06 |
2023-11-09 |
Genmab A/S |
Methods of treating cancer with anti-tissue factor antibody-drug conjugates
|
WO2024054436A1
(en)
|
2022-09-06 |
2024-03-14 |
Alexion Pharmaceuticals, Inc. |
Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
|
WO2024097816A1
(en)
|
2022-11-03 |
2024-05-10 |
Seagen Inc. |
Anti-avb6 antibodies and antibody-drug conjugates and their use in the treatment of cancer
|
WO2024108053A1
(en)
|
2022-11-17 |
2024-05-23 |
Sanofi |
Ceacam5 antibody-drug conjugates and methods of use thereof
|
WO2024105205A1
(en)
|
2022-11-17 |
2024-05-23 |
Bayer Aktiengesellschaft |
Antibody-drug conjugates (a2dcs) with enzymatically cleavable groups
|